News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ERYtech Pharma Provides Business Update And Reports Financial Highlights For Third Quarter 2016



11/4/2016 11:17:30 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
LYON, France, Nov. 03, 2016 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today provided a business update and reported its financial results for the quarter ended September 30, 2016.

Third Quarter and Recent Business Highlights

* ERYTECH’s MAA for GRASPA® to treat relapsed and refractory ALL, submitted in September 2015, remains under review by the EMA’s Committee for Human Medicinal Products (CHMP). The Company received its Day 180 List of Outstanding Issues and expects to be in a position to receive an opinion from the CHMP regarding the approvability of GRASPA® during 2017.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES